February 26, 2009 — A new urine test that detects a gene fusion associated with prostate cancer is highly accurate in detecting the disease, yielding a high specificity relative to biopsy outcome.

The test, known as the T2:ERG urine test, detects the fusion of 2 genes: TMPRSS2 and ERG. It also has a sensitivity that is consistent with the roughly 50% prevalence of these gene fusions in men with prostate cancer.

Test scores also significantly correlate with 4 indicators of prostate cancer aggressiveness.

"The goals for the next generation of prostate cancer tests are not just detection but to distinguish between aggressive and indolent disease," said Jack Groskopf, PhD, director of research and development in the Cancer Diagnostics Division of Gen-Probe Incorporated, in San Diego, California, which developed the test.